A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age

Trial Profile

A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Influenza A H1N1 H3N2 influenza B Yamagata Victoria vaccine-Novartis (Primary) ; MF 59
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis; Novartis Vaccines; Seqirus
  • Most Recent Events

    • 19 Apr 2018 Results published in the Media Release
    • 19 Apr 2018 This study was led by Dr. Vesikari, according to a Seqirus media release.
    • 19 Apr 2018 The Lancet Respiratory Medicine published results from this trial, according to a Seqirus media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top